20 January 2026
Where Is the White Space in Drug Development?
Jonathan Tobin Partner at Brandon Capital At Brandon Capital we spend most of our time creating and building companies discovering and developing new medicines that have the potential to deliver transformational benefit in important diseases. We will always invest in “traditional” (and competitive) areas such as oncology and immunology, but we’ve also never been […]
